The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This study is being done to see if the investigational drug Ranibizumab (RBZ) given by
injection into the eye, is safe and effective to use in people with diabetic macular edema
(DME). The investigators want to compare RBZ to laser treatment which is the current standard
way to treat DME.
RBZ blocks a growth factor that is thought to be involved in the formation of abnormal blood
vessels that cause loss of vision in patients with DME.
Phase:
Phase 2
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
Genentech, Inc. Juvenile Diabetes Research Foundation